Alli

Alli is the first OTC weight loss pill to be approved by the FDA. Alli diet pill ranked #6 on our top diet pills review. Alli is a non-prescription diet pill that simply reduces the body’s amount of fat absorption. Alli has come up with a weight loss program to go along with the diet pill and is appropriate for obese patients 18 years and older.
The active ingredient in Alli is the generic drug orlistat. Orlistat is also the active ingredient in the branded prescription diet medication, Xenical. Alli has half the dosage of orlistat than Xenical, due to this reduced quantity of the active ingredient Alli has been considered safe enough for people to use without the need of a doctor’s prescription. It is similar to Meridia from this point of view but it’s effectiveness is way bellow it
.
Alli is recommended to be used by obese persons, meaning persons with a BMI of 25 or above, a BMI of 30+.
Alli is not recommended for everyone. DON’T USE Alli if you:
• have a healthy BMI
• are taking cyclosporine
• had an organ transplant
• have gastrointestinal problems
• have problems absorbing food
• are taking blood-thinning medication
• have diabetes
• have thyroid diseases
Because Alli decreases the absorption of fat, fat soluble vitamins like vitamins A, D, E, and K will be diminished as well. It is necessary and highly recommended to take vitamin supplements to avoid nutrient deficiencies.
Alli like any diet pill on the market has it’s side effects. Here are some possible side effects to this drug:
• Flatulence
• Oily anal discharge
• Loose stools or diarrhe
• More frequent bowel movements
• Hard-to-control bowel movements
As we mentioned before Alli is not that of a strong diet pill, so if you are considering using this pill you must not expect extreme weight loss in a few weeks. Alli is a long term diet pill, so if you are looking for something quick and more efficient we recommend acomplia or xenical.
Check a list of online pharmacies from where you can buy Alli or check the prices of Alli by clicking here

No Comments
No comments yet.